Publikationen

Grundlegende Voraussetzung für die flächendeckende Verbesserung der Behandlungskonzepte ist die Publikation der Forschungsergebnisse. iOMEDICO unterstützt die internationalen Richtlinien zu Transparenz und Veröffentlichung von medizinischen Forschungsergebnissen.

Wir präsentieren unsere Daten regelmäßig auf nationalen und internationalen Kongressen. Unsere Publikationen erscheinen in wissenschaftlich renommierten, internationalen Fachzeitschriften. Autoren sind die Studienleiter, Prüfärzte mit besonders hoher Patiententeilnahme und Wissenschaftler von iOMEDICO.

TITEL
STUDIE
JAHR
Real-life treatment and outcome data for patients with advanced NSCLC receiving treatments containing bevacizumab – data from the clinical registry on lung cancer (TLK).

Steffens, C.-C., Tessen, H.W., Losem, C., Münz, M., Jänicke, M., Spring, L., Marschner, N., 2014.

Oncol Res Treat 37 (suppl 5)(P217), 64. doi:10.1159/000368945

Abstract

Download

Indikation: Lung Cancer, Lungenkarzinom / Veranstaltung: DGHO / Journal: Oncology Research and Treatment
TLK
2014
Effectiveness of bevacizumab beyond progression in patients with metastatic colorectal cancer – data from the clinical TKK registry.

Schnell, R., Musch, R., Broszeit-Luft, S., Harde, J., Kopfmann, S., Jänicke, M., Marschner, N., 2014.

Oncol Res Treat 37(Suppl.5)(V332), 101. doi:10.1159/000368945

Abstract

Indikation: Colorectal Cancer, Kolorektalkarzinom / Veranstaltung: DGHO / Journal: Oncology Research and Treatment
TKK
2014
Patients with brain metastases from advanced or metastatic renal cell carcinoma – Data from the clinical RCC Registry.

Müller, L., Goebell, P., Reichert, D., Krieger, J., Jänicke, M., Harde, J., Koska, M., Marschner, N., 2014.

Oncol Res Treat 37 (suppl.5)(P287), 91. doi:10.1159/000368945

Abstract

Download

Indikation: Urogenital Tumors, Urogenitale Tumore / Veranstaltung: DGHO / Journal: Oncology Research and Treatment
TNK
2014
No impact of first-line systemic therapy on quality of life of patients with metastatic breast cancer? Data from the MaLife-project.

Marschner, N., Tesch, H., Karcher, A., Ammon, A., Nusch, A., Boller, E., Spring, L., Jänicke, M., 2014.

Oncol Res Treat 37 (suppl 5)(V371), 111. doi:10.1159/000368945

Abstract

Indikation: Breast Cancer, Mammakarzinom / Veranstaltung: DGHO / Journal: Oncology Research and Treatment
TMK
2014
Treatment of chemotherapy-induced neutropenia with Lipegfilgrastim (Lonquex®): First interim analysis of the non-interventional study NADIR.

Kurbacher, C., Diel, I., Egert, M., Fietz, T., Hurtz, H., Lück, A., Weide, R., Wolff, T., Zaiss, M., Teichmann, B., Harde, J., Scheuerlein, R., 2014.

Oncol Res Treat 37(suppl 5)(P512). doi:10.1159/000368945

Abstract

Indikation: Supportive Therapy, Supportivtherapie / Veranstaltung: DGHO / Journal: Oncology Research and Treatment
NADIR
2014
1st-line treatment with BR and FCR in patients with chronic lymphocytic leukamia.

Knauf, W., Abenhardt, W., Engel, E., Grugel, R., Harde, J., Jänicke, M., Marschner, N., 2014.

Oncol Res Treat 37 (suppl5)(P186), 50. doi:10.1159/000368945

Abstract

Download

Indikation: Haemoblastoma, Hämoblastosen / Veranstaltung: DGHO / Journal: Oncology Research and Treatment
TLN
2014
Long-term side effects of curative treatment for breast cancer – data from the MaTox project.

Hurtz, H.-J., Tesch, H., Göhler, T., Hutzschenreuter, U., Harde, J., Kruggel, L., Marschner, N., 2014.

Oncol Res Treat 37 (suppl 5)(V370), 110. doi:10.1159/000368945

Abstract

Indikation: Breast Cancer, Mammakarzinom / Veranstaltung: DGHO / Journal: Oncology Research and Treatment
TMK
2014
Multiple myeloma and neurotoxicity: Patient-reported and physician-recorded findings from the German prospective TLN Registry and the LyTox project.

Hurtz, H.-J., Knauf, W., Hutzschenreuter, U., Mittermüller, J., Grugel, R., Harde, J., Boller, E., Hartmann, H., Marschner, N., 2014.

Oncol Res Treat 37 (suppl 5)(P861), 286–287. doi:10.1159/000368945

Abstract

Download

Indikation: Haemoblastoma, Hämoblastosen / Veranstaltung: DGHO / Journal: Oncology Research and Treatment
TLN
2014
Real-life treatment of patients with advanced pancreatic cancer in Germany – data from the clinical registry pancreatic cancer (TPK).

Hegewisch-Becker, S., Hofheinz, R.-D., Hartmann, H., Kopfmann, S., Marschner, N., 2014.

Oncol Res Treat 37(Suppl.5)(P274), 86. doi:10.1159/000368945

Abstract

Download

Indikation: Pancreatic Cancer, Pankreaskarzinom / Veranstaltung: DGHO / Journal: Oncology Research and Treatment
TPK
2014
Maintenance strategy with fluoropyrimidines (FP) plus bevacizumab (Bev), Bev alone, or no treatment, following a standard combination of RP, Oxaliplatin (Ox), and Bev as first-line treatment for patients with metastatic colorectal cancer (mCRC): Results of the AIO KRK 0207 phase III study.

Hegewisch-Becker, S., Arnold, D., Lerchenmüller, C., Killing, B., Depenbusch, R., Steffens, C.-C., Al-Bartan, S.-E., Lange, T., Dietrich, G., Stoehlmacher, J., Reinacher-Schick, A., Tannapfel, A., Quidde, J., Hinke, A., Schmoll, H.-J., Graeven, U., 2014.

Oncol Res Treat 37 (Suppl.5)(V327), 99 doi:10.1159/000368945

Abstract

Indikation: Colorectal Cancer, Kolorektalkarzinom / Veranstaltung: DGHO / Journal: Oncology Research and Treatment
AIO KRK 0207
2014